Rasburicase Injection bulk supplier for pharma manufacturers

Rasburicase Injection 7.5 mg/15 mL vial Suppliers & Bulk Manufacturers

Available Forms: IV infusion

Available Strengths: 7.5 mg/15 mL vial

Reference Brands: Elitek(US)

Rasburicase Injection 7.5 mg/15 mL is used to treat tumor lysis syndrome (TLS) in cancer patients, particularly those with leukemia and lymphoma. Available in both the U.S. and EU, it helps prevent kidney damage by converting uric acid into allantoin. Essential for oncology B2B distribution.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Rasburicase Injection 7.5 mg/15 mL is a critical treatment for tumor lysis syndrome (TLS), commonly associated with hematologic cancers like leukemia and lymphoma. By converting uric acid into allantoin, Rasburicase reduces the risk of kidney damage caused by high uric acid levels. Approved in both the U.S. and EU, Elitek (brand name in the U.S.) is supplied as a sterile IV solution for infusion. Rasburicase is essential for B2B pharmaceutical distribution, supporting oncology care centers, hospitals, and clinics with essential treatment for high-risk cancer patients undergoing chemotherapy.

Rasburicase Injection — third party manufacturing & bulk supply

Rasburicase Injection 7.5 mg/15 mL vial is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Rasburicase Injection is supplied as IV infusion — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Rasburicase Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Rasburicase Injection →

Back to Listing

Frequently Asked Questions

Rasburicase Injection is listed as IV infusion in 7.5 mg/15 mL vial. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Rasburicase Injection is referenced against Elitek(US). Reference brands are shown for identification only and remain the property of their respective trademark owners.